Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Olodaterol in Severe Renal Impairment
NCT02172118Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve 0-4 hours and Maximum concentration. Started Aug 2009; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02172118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172118.